T2 Biosystems Inc (OQ:TTOO)
Business Focus: Advanced Medical Equipment & Technology
| Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 101 Hartwell Ave LEXINGTON MA 02421-3125 |
| Tel: | 1-415-9375406 |
| Website: | https://www.t2biosystems.com |
| IR: | See website |
| Key People | ||
| John J. Sperzel Chairman of the Board, President, Chief Executive Officer | John M. Sprague Chief Financial Officer | Michael Gibbs Senior Vice President, General Counsel |
| Roger Smith Senior Vice President of Science Research and Development | Brett Giffin Chief Commercial Officer | |
| Business Overview |
| T2 Biosystems, Inc. is an in vitro diagnostics company focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. Its technology enables detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its focus includes three areas: sepsis, bioterrorism, and Lyme disease. The Company's products include the T2Dx Instrument, the T2Bacteria Panel, the T2Candida Panel, the T2Resistance Panel, and the T2Biothreat Panel, and are powered by the T2 Magnetic Resonance (T2MR) technology. It also has an active pipeline of products, including the United States T2Resistance Panel, the Candida auris test, and the T2Lyme Panel. T2Dx Instrument is a fully automated instrument that is capable of running a range of diagnostic tests from patient samples. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, T2 Biosystems Inc revenues decreased 68% to $7.2M. Net loss applicable to common stockholders decreased 20% to $50.1M. Revenues reflect Contribution Revenue segment decrease of 96% to $423K, Consumables segment decrease of 41% to $4.8M, domestic segment decrease of 76% to $4.5M, international segment decrease of 31% to $2.7M. |
| Employees: | 113 as of Dec 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $49.51M as of Dec 31, 2023 |
| Annual revenue (TTM): | $7.19M as of Dec 31, 2023 |
| EBITDA (TTM): | -$46.27M as of Dec 31, 2023 |
| Net annual income (TTM): | -$50.08M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$48.33M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $25.60M as of Dec 31, 2023 |
| Shares outstanding: | 8,792,950 as of Apr 12, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.